---
title: "Gland Pharma Ltd (GLAND) — Share Price, Financials & Analysis"
symbol: "GLAND"
company: "Gland Pharma Ltd"
canonical: "https://tapetide.com/stocks/GLAND"
isin: "INE068V01023"
nse_symbol: "GLAND"
bse_code: "543245"
sector: "Healthcare"
industry: "Pharmaceuticals"
market_cap_cr: 47638.71
generated_at: "2026-09-13T19:57:12.391Z"
---

# Gland Pharma Ltd (GLAND)

Canonical page: https://tapetide.com/stocks/GLAND

## Company

- **NSE Symbol:** GLAND
- **BSE Code:** 543245
- **ISIN:** INE068V01023
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2020-11-20
- **CEO:** Mr. Srinivas Sadu
- **Employees:** 4351
- **Face Value:** ₹1
- **F&O Eligible:** No
- **Website:** glandpharma.com

## About

Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. We operate primarily under a business to business (B2B) model and have an excellent track record in the development, manufacturing and marketing of complex injectables. This presence across the value chain has helped us witness exponential growth. We are promoted by Shanghai Fosun Pharma, a global pharmaceutical major.

## Latest Price

- **Price:** ₹2922.3
- **Change:** -24.6 (-0.83%)
- **Open:** ₹2940
- **Day High:** ₹2950.1
- **Day Low:** ₹2882
- **Previous Close:** ₹2946.9
- **Volume:** 389004
- **As Of:** 2026-09-11T10:24:47+00:00

## Key Fundamentals

Observed at 2026-09-11T04:36:07.633328Z.

- **Market Cap:** ₹47638.71 Cr
- **Classification:** Midcap
- **P/E (reported):** 43.1
- **P/E (TTM):** 42.67
- **EPS (TTM):** ₹68.49
- **EPS (reported):** ₹43.83
- **Book Value:** ₹627.88
- **Price to Book:** 4.7
- **Dividend Yield:** 0.68%
- **ROE:** 9.92%
- **ROCE:** 13.74%
- **Debt to Equity:** 0.03
- **Revenue (yearly):** ₹6747 Cr
- **Net Income:** ₹1027.3 Cr
- **EBITDA:** ₹1945.9 Cr
- **52-Week High:** ₹3042
- **52-Week Low:** ₹1573.6
- **RSI (14):** 61.3

## Tapetide Score

- **Score:** 56 / 100
- **Score date:** 2026-09-04
- **Archetype:** Average Quality, Undemanding Price
- **What it means:** The financials sit mid-range rather than strong, and the multiple is not demanding. Nothing here stands out in either direction, so the read comes down to which single pillar you weight most and whether the next results move it off the middle.
- **Pillar profile:** Quality: Average · Valuation: Cheap · Momentum: Rising
- **Percentile:** 74.1 (of 4473 scored stocks)
- **Confidence:** 100%
- **Data coverage:** 100%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 84.99 | 9% |
| growth | 51.94 | 9% |
| momentum | 93.51 | 12% |
| ownership | 30.03 | 24% |
| quality | 56.54 | 22% |
| valuation | 69.68 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 39.1%

### Weaknesses

- Stock is trading at 4.65 times its book value
- Company has a low return on equity of 9.29% over last 3 years.
- Promoter holding has decreased over last 3 years: -6.09%

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | 12.75% | 3.47% | 30.43% |
| ebitda margin growth | -11.83% | 13.41% | 11.96% | -23.09% |
| net income growth | -13.55% | 47.07% | 8% | 1% |
| revenue growth | 0.39% | 15.73% | 21% | 13% |
| roce | -14.83% | 20.1% | 9.83% | 14.66% |
| roe | -13.56% | 30.01% | 8.8% | -41.41% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 1373 | 1545 | 1537 | 1402 | 1406 | 1384 | 1425 | 1506 | 1487 | 1695 | 1743 | 1800 |
| Expenses | 1049 | 1189 | 1179 | 1137 | 1109 | 1024 | 1077 | 1138 | 1173 | 1260 | 1230 | 1311 |
| Operating Profit | 324 | 356 | 359 | 264 | 297 | 360 | 348 | 368 | 314 | 435 | 513 | 489 |
| OPM % | 24 | 23 | 23 | 19 | 21 | 26 | 24 | 24 | 21 | 26 | 29 | 27 |
| Other Income | 53 | 37 | 42 | 51 | 60 | 58 | 44 | 58 | 84 | 39 | 111 | 61 |
| Interest | 6 | 5 | 10 | 6 | 6 | 23 | 7 | 12 | 8 | 4 | 10 | 4 |
| Depreciation | 81 | 105 | 93 | 92 | 94 | 96 | 96 | 101 | 106 | 108 | 109 | 111 |
| Profit before tax | 290 | 283 | 298 | 218 | 257 | 299 | 288 | 313 | 284 | 362 | 506 | 435 |
| Tax % | 33 | 32 | 35 | 34 | 36 | 32 | 35 | 31 | 35 | 28 | 28 | 27 |
| Net Profit | 194 | 192 | 192 | 144 | 164 | 205 | 187 | 215 | 184 | 261 | 367 | 317 |
| EPS in Rs | 11.78 | 11.65 | 11.68 | 8.73 | 9.93 | 12.42 | 11.32 | 13.08 | 11.15 | 15.87 | 22.26 | 19.21 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 2633 | 3463 | 4401 | 3625 | 5665 | 5616 | 6431 | 6725 |
| Expenses | 1678 | 2161 | 2890 | 2600 | 4332 | 4348 | 4801 | 4974 |
| Operating Profit | 955 | 1302 | 1510 | 1025 | 1333 | 1269 | 1630 | 1751 |
| OPM % | 36 | 38 | 34 | 28 | 24 | 23 | 25 | 26 |
| Other Income | 139 | 135 | 224 | 184 | 170 | 214 | 292 | 296 |
| Interest | 7 | 3 | 5 | 7 | 26 | 42 | 33 | 26 |
| Depreciation | 95 | 99 | 110 | 147 | 345 | 378 | 424 | 434 |
| Profit before tax | 993 | 1335 | 1619 | 1055 | 1133 | 1063 | 1465 | 1587 |
| Tax % | 22 | 25 | 25 | 26 | 32 | 34 | 30 | — |
| Net Profit | 773 | 997 | 1212 | 781 | 772 | 699 | 1027 | 1129 |
| EPS in Rs | 49.88 | 60.94 | 73.75 | 47.42 | 46.9 | 42.4 | 62.35 | 68.49 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 43 | 42 | 32 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
| Reserves | 3631 | 5887 | 7141 | 7942 | 8707 | 9134 | 10341 |
| Borrowings | 5 | 5 | 5 | 4 | 372 | 314 | 284 |
| Other Liabilities | 435 | 588 | 671 | 814 | 1515 | 1708 | 1807 |
| Total Liabilities | 4086 | 6496 | 7834 | 8778 | 10611 | 11173 | 12449 |
| Fixed Assets | 968 | 954 | 1502 | 1571 | 3947 | 4147 | 4492 |
| CWIP | 188 | 338 | 191 | 177 | 238 | 151 | 342 |
| Investments | 0 | 0 | 155 | 0 | 0 | 0 | 0 |
| Other Assets | 2929 | 5204 | 5986 | 7030 | 6426 | 6875 | 7614 |
| Total Assets | 4086 | 6496 | 7834 | 8778 | 10611 | 11173 | 12449 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 701 | 605 | 791 | 364 | 997 | 915 | 1031 |
| Cash from Investing Activity | -761 | -1520 | -999 | 1211 | -1749 | 1718 | 188 |
| Cash from Financing Activity | -7 | 1238 | 35 | 15 | -799 | -433 | -417 |
| Net Cash Flow | -67 | 323 | -174 | 1590 | -1552 | 2199 | 803 |
| Free Cash Flow | 530 | 377 | 269 | 141 | 599 | 521 | 538 |
| CFO/OP | 99 | 70 | 79 | 66 | 98 | 100 | 91 |

### Ratios

| Item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 83 | 71 | 99 | 88 | 100 | 99 | 107 |
| Inventory Days | 250 | 312 | 205 | 421 | 278 | 294 | 284 |
| Days Payable | 82 | 97 | 80 | 127 | 129 | 143 | 136 |
| Cash Conversion Cycle | 251 | 286 | 225 | 382 | 250 | 250 | 255 |
| Working Capital Days | 161 | 169 | 168 | 242 | 155 | 173 | 145 |
| ROCE % | — | 28 | 25 | 15 | 14 | 12 | 15 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 57.86% | 57.86% | 57.86% | 51.83% | 51.83% | 51.83% | 51.83% | 51.83% | 51.83% | 51.83% | 51.83% | 51.77% |
| FIIs | 4.91% | 4.05% | 3.59% | 6.88% | 4.47% | 5.04% | 6.9% | 7.39% | 7.91% | 7.58% | 7.3% | 8.74% |
| DIIs | 22.45% | 23.14% | 25.23% | 32.83% | 35.37% | 34.8% | 33.27% | 32.85% | 32.64% | 32.98% | 33.35% | 30.44% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 4.52% | 3.79% | 3.28% | 3.33% | 3.28% | 3.3% | 2.99% | 2.91% | 2.57% | 2.57% | 2.53% | 3.5% |
| Others | 10.27% | 11.17% | 10.04% | 5.12% | 5.04% | 5.04% | 5.01% | 5.02% | 5.06% | 5.04% | 4.98% | 5.55% |
| No. of Shareholders | 161627 | 136021 | 122375 | 122665 | 122358 | 121075 | 113788 | 110671 | 97151 | 94578 | 91500 | 108266 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Buy
- **Buy / Neutral / Sell:** 11 / 5 / 3

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 2929.85 | Sell |
| EMA (10) | 2931.25 | Sell |
| SMA (20) | 2891.94 | Buy |
| EMA (20) | 2881.12 | Buy |
| SMA (50) | 2691.68 | Buy |
| EMA (50) | 2708.09 | Buy |
| SMA (100) | 2410.22 | Buy |
| EMA (100) | 2480.36 | Buy |
| SMA (200) | 2072.8 | Buy |
| EMA (200) | 2223.57 | Buy |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 58.42 | Neutral |
| MACD (12,26,9) | 76.07 | Sell |
| Stochastic (14,3,3) | 71.09 | Neutral |
| ADX (14) | 38.6 | Buy |
| Williams %R (14) | -45.02 | Neutral |
| ATR (14) | 90.98 | High Volatility |
| ROC (12) | 0.66 | Buy |
| Stoch RSI (14) | 0 | Buy |
| UO (7,14,28) | 58.29 | Neutral |

## Analyst Ratings

| Recommendation | Analysts | Share |
| --- | --- | --- |
| Buy | 11 | 73.33% |
| Hold | 1 | 6.67% |
| Sell | 3 | 20% |

Based on 15 analyst ratings, observed at 2026-09-11T04:36:09.967967+00:00.

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-10 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=204b12a7-5d9f-4967-92b2-92142194b193.pdf) |
| 2026-09-08 | [Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=97A1EC9B_A32B_4C08_A46C_477FDAA9F50E_124606.pdf) |
| 2026-09-08 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=54ad8654-1c3a-47c6-bb01-1c7e771b1b0d.pdf) |
| 2026-09-04 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=74e82401-d538-433b-bde3-522923f81848.pdf) |
| 2026-09-01 | [Conclusion Of USFDA Inspection At Companys Facilities Situated At Visakhapatnam](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d0e2b684-1094-40ea-908e-9c07761e1dd9.pdf) |
| 2026-08-31 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=35aaa265-e4a4-4e1c-880b-8609e3d3e9cb.pdf) |
| 2026-08-26 | [Shareholder Meeting / Postal Ballot-Scrutinizers Report](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=85e135ae-dbd7-476a-a8e4-67b862458f41.pdf) |
| 2026-08-25 | [Shareholder Meeting / Postal Ballot-Outcome of AGM](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5616a115-0467-4546-9cde-e86b4d5d311d.pdf) |
| 2026-08-23 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e0832785-235e-485c-a089-bca73d64c79b.pdf) |
| 2026-08-14 | [Announcement under Regulation 30 (LODR)-Change in Management](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=169f141f-783a-4278-b811-6d99e9c7885b.pdf) |

### Earnings Call Transcripts

| Date | Document |
| --- | --- |
| 2026-08-17 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b416484e-ca43-431c-abb8-02d9bb92d3d1.pdf) |
| 2026-05-20 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b7c08c7d-b2f3-4ca2-9c32-a5d3cd8c5734.pdf) |
| 2026-02-03 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=937f9d7d-d366-4170-931d-281f106b2a1b.pdf) |
| 2025-11-07 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e8b06a13-ec55-4396-9096-329d957bcec0.pdf) |
| 2025-08-11 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=521fa767-e46d-43a5-9df7-582e1a2e5c5c.pdf) |
| 2025-05-27 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e6c12ae4-ea0b-4fd5-9091-a9bf276115fb.pdf) |
| 2025-02-10 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2f76772f-96b3-4b3b-a419-985c7474a147.pdf) |
| 2024-11-11 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5f92d2fd-f0bf-40fe-b4bf-297d87627c5f.pdf) |
| 2024-08-12 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e8f3b7a8-e203-4f66-9959-14e90a750195.pdf) |
| 2024-05-29 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=25470e59-a9c1-41ed-b6e1-31a07154e694.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-08-10 | [Unaudited Financial Results For The Quarter Ended June 30 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=20ebb92c-c4dd-457f-8fc9-7cea4295c55e.pdf) |
| 2026-05-15 | [Q4FY26 Audited Financial Results](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fa2147e2-7632-4b23-a0b7-44550ab428ff.pdf) |
| 2026-01-28 | [Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=abbfef19-482c-47db-b669-28e470f45bbe.pdf) |
| 2025-11-03 | [Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ecaea78b-a751-4978-a469-e3be6ffd5e17.pdf) |
| 2025-08-05 | [Unaudited Financial Results For The Quarter Ended June 30 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ee44c072-4ee8-4c49-8667-ada77a9b3440.pdf) |
| 2025-02-03 | [Unaudited Financial Results For The Quarter Ended December 31 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8cdd8edb-0ae7-45a7-adaf-adc738b16a65.pdf) |
| 2024-11-04 | [Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3b216c63-706e-4285-84b9-7b82bde14ea2.pdf) |
| 2024-08-06 | [Unaudited Financial Results For Q1 FY25](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a5a45625-b123-4584-aba5-b026124a87cb.pdf) |
| 2024-05-22 | [Audited Financial Results For The Financial Year Ended March 31, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2b23900e-1d06-4816-8fce-7568a8d59331.pdf) |
| 2024-02-14 | [The Board Of Directors At Its Meeting Held On February 14, 2024 Has Inter-Alia Approved The Unaudited Financial Results Of The Company For The Quarter And Nine Months Ended December 31, 2023](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6c062461-ac1d-4c12-814a-2da18da79346.pdf) |

### Investor Presentations

| Date | Document |
| --- | --- |
| 2026-08-10 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=86f0ddbe-989b-4b65-8986-545f092e94f9.pdf) |
| 2026-05-15 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0a94d086-0e08-42e8-bee0-18b4e866188c.pdf) |
| 2026-01-28 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bf4106eb-8744-48f5-b7e3-2fb0d09d8755.pdf) |
| 2025-11-03 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=90359eb7-19e0-41c8-b0b9-e9c3541f0a24.pdf) |
| 2025-08-05 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d4e532e4-80dd-4d42-a96e-b9c7adccfe7a.pdf) |
| 2025-05-20 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d73d15ea-c7e4-49eb-9235-857aea24cf30.pdf) |
| 2025-02-03 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f364bfc8-c127-40b4-a9a1-280ae7101498.pdf) |
| 2024-11-04 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=33b7fb4d-ac78-47a5-9afb-926ea738b5fc.pdf) |
| 2024-08-06 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c7325620-6f8b-4ded-a826-2765c084a968.pdf) |
| 2024-05-22 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8c27b6df-3aa7-43c9-8b5e-74c3bb1c1558.pdf) |

### Earnings Call Recordings

| Date | Document |
| --- | --- |
| 2026-08-10 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7e8d9430-561f-4bb1-8892-e590c8dd0b5d.pdf) |
| 2026-01-28 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c1de4697-ae87-46fd-b9d9-9b94a25b7a43.pdf) |
| 2025-11-03 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ff0bb70b-d3e0-48ec-befc-dcb93e87e690.pdf) |
| 2025-05-20 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d13dadea-3f4f-49c3-80be-1480764dbef3.pdf) |
| 2024-02-14 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4e41cabc-7012-440e-8542-05556ea7b46b.pdf) |
| 2023-11-06 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ac766eae-723c-4bdc-8051-787ba2f9fd59.pdf) |
| 2023-08-07 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=637ee07b-6b74-4bc8-9ef8-1e740186c675.pdf) |
| 2023-05-18 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=710703c1-636c-4e6e-a93b-eff81e86a43a.pdf) |
| 2023-01-23 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=128803ed-675e-42de-8661-a7fca66f2f42.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/e8b06a13-ec55-4396-9096-329d957bcec0.pdf) |
| Nov 2024 | [Concall - Nov 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/5f92d2fd-f0bf-40fe-b4bf-297d87627c5f.pdf) |
| Nov 2023 | [Concall - Nov 2023](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0602e943-005f-4674-8890-57ab3f30644f.pdf) |
| Nov 2023 | [Concall - Nov 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/0602e943-005f-4674-8890-57ab3f30644f.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b7c08c7d-b2f3-4ca2-9c32-a5d3cd8c5734.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachLive/b7c08c7d-b2f3-4ca2-9c32-a5d3cd8c5734.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/0a94d086-0e08-42e8-bee0-18b4e866188c.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachLive/0a94d086-0e08-42e8-bee0-18b4e866188c.pdf) |
| May 2025 | [Concall - May 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/e6c12ae4-ea0b-4fd5-9091-a9bf276115fb.pdf) |
| May 2024 | [Concall - May 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/25470e59-a9c1-41ed-b6e1-31a07154e694.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 9 Mar - Analyst/institutional investor meetings and plant visit scheduled March 12, 13, 17, 2026 (Investec, SBI, Capital World). | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 9 Mar - Analyst/institutional investor meetings and plant visit scheduled March 12, 13, 17, 2026 (Investec, SBI, Capital World).](https://www.bseindia.com/xml-data/corpfiling/AttachHis/fb5ea705-78ae-469d-b658-3230212381c7.pdf) |
| 9 Apr - Board reappoints Naina Lal Kidwai as independent director for five years from May 17, 2026. | [Board Meeting Outcome for Reappointment Of Ms. Naina Lal Kidwai As An Independent Director, Subject To Shareholders Approval 9 Apr - Board reappoints Naina Lal Kidwai as independent director for five years from May 17, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/277f6a33-9cbb-4471-9a55-c9e8174425ea.pdf) |
| 9 Apr - Board reappointed Naina Lal Kidwai as independent director for second term from May 17, 2026 to May 16, 2031. | [Announcement under Regulation 30 (LODR)-Change in Directorate 9 Apr - Board reappointed Naina Lal Kidwai as independent director for second term from May 17, 2026 to May 16, 2031.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/6d7a1791-9a1c-42cb-b0bc-52150daae1c6.pdf) |
| 6 Mar - GST order dated March 5, 2026: tax INR 5,03,51,468 and penalty INR 1,25,87,867; company to appeal. | [Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 6 Mar - GST order dated March 5, 2026: tax INR 5,03,51,468 and penalty INR 1,25,87,867; company to appeal.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/073ffe33-3d1f-437d-aead-ecd156d0047d.pdf) |
| 6 Apr - Prasadha Rao Lysetti appointed Sr. Vice-President (Head-Operations) effective April 6, 2026. | [Announcement under Regulation 30 (LODR)-Change in Management 6 Apr - Prasadha Rao Lysetti appointed Sr. Vice-President (Head-Operations) effective April 6, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/6eb470a4-c335-4f64-b59f-6736ea82d693.pdf) |
| 4 Mar - Tentative USFDA approval for Brimonidine Tartrate Ophthalmic Solution 0.025% (OTC); product had ~USD39m US sales (12 months to Sep 2025). | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 4 Mar - Tentative USFDA approval for Brimonidine Tartrate Ophthalmic Solution 0.025% (OTC); product had ~USD39m US sales (12 months to Sep 2025).](https://www.bseindia.com/xml-data/corpfiling/AttachHis/1215b008-435e-46d1-ac24-6bd1d1e756ae.pdf) |
| 3 Mar - CEO Shyamakant Giri resigns, effective April 30, 2026; resignation dated February 24, 2026. | [Announcement under Regulation 30 (LODR)-Resignation of Chief Executive Officer (CEO) 3 Mar - CEO Shyamakant Giri resigns, effective April 30, 2026; resignation dated February 24, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/5f3206ee-3975-4ffa-868e-d312ed8b135d.pdf) |
| 27 Mar - Trading window closed from March 28, 2026 until 48 hours after audited results for quarter/year ending March 31, 2026. | [Closure of Trading Window 27 Mar - Trading window closed from March 28, 2026 until 48 hours after audited results for quarter/year ending March 31, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/4664dcde-560c-4b9b-bdc7-c9acdf3eccf8.pdf) |
| 27 Apr - Clarifies annual special resolution approval for Ms. Naina Lal Kidwai’s reappointment and remuneration from FY27-FY31. | [Clarification With Respect To The Announcement Made On 13Th April , 2026, Regarding Postal Ballot Notice 27 Apr - Clarifies annual special resolution approval for Ms. Naina Lal Kidwai’s reappointment and remuneration from FY27-FY31.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/7165fe5c-9272-4714-811a-e5875631634b.pdf) |
| 21 Apr - Gland Pharma to host Q4 FY26 earnings call on May 15, 2026 at 18:30 IST. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 21 Apr - Gland Pharma to host Q4 FY26 earnings call on May 15, 2026 at 18:30 IST.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/c7203643-9e22-45bc-8962-4b9d874c2022.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Annual Report 2026 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/fc85ba48-93f1-450b-9336-f0490e6172fa.pdf) |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/e2c13564-f778-4289-b41d-f77fa88c1c3b.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/6ea4005e-beba-4a51-b5e2-bd205e23c8a4.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b84f37da-ded1-4d8c-8c05-6102956ff833.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:57:12.391Z.